Kymera Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
All right, hello and welcome. My name is Michael Schmidt. I'm one of the biotech analysts at Guggenheim. It is my great pleasure to introduce the next company, Kymera. With us today, we have Nello Mainolfi, the CEO, as well as Jared Gollob, Chief Medical Officer. Welcome, and thanks for joining us.
Thanks, Michael.
Questions & Answers
So we'll jump right into Q&A. So maybe to start out with, the number of companies with in-house TPD platforms or part of that interest in the space has expanded significantly in recent years, including small private companies, public pure plays and then large pharma companies as well. Can you talk about the Kymera technology platform in context of protein degradation in general and how you've positioned the company in the category?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
